ghk-cu intradermal injection clinical trial In Vitro and in Vivo Studies of pH-Sensitive GHK-Cu-Incorporated Polyaspartic and Polyacrylic Acid Superabsorbent Polymer GHK-Cu Copper Peptide: Dosage, Before
Description
Its activity has been associated with reduced permeability disturbances and improved resistance to mucosal injury, particularly in models involving non-steroidal anti-inflammatory drug exposure (10)
0.03) mg/L ( p = 0.01) but not by metformin/placebo, and with no significant difference between treatments
Might see an ENT soon if this continues awhile longer
The most rigorous clinical study was a double-blind, placebo-controlled trial in 16 chronic insomnia patients published by Schneider-Helmert and Schoenenberger in Neuropsychobiology
